Effect of Glucagon-like Peptide-1 (GLP-1) Receptor Agonist Stimulation on Smoking Consumption in Type 2 Diabetes Patients
NCT ID: NCT06924697
Last Updated: 2025-05-31
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
ENROLLING_BY_INVITATION
Clinical Phase
NA
Total Enrollment
46 participants
Study Classification
INTERVENTIONAL
Study Start Date
2025-06-21
Study Completion Date
2026-07-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Diabetes has become an increasingly serious global health issue. In 2024, approximately 537 million adults were living with diabetes, and this number is projected to rise to 783 million by 2045, representing a 46% increase. Against the backdrop of a growing global diabetes epidemic, smoking among individuals with diabetes poses a significant threat, further exacerbating clinical and public health burdens. Despite over 50 years of tobacco control efforts, smoking remains one of the greatest public health threats in history, causing more than 8 million deaths annually worldwide. Among these, over 7 million deaths result from direct tobacco use, while approximately 1.3 million deaths are attributed to secondhand smoke exposure.
Recent studies have shown that smoking increases the risk of developing prediabetes and diabetes. Moreover, individuals with diabetes who smoke have a higher risk of all-cause mortality, worsened chronic diabetic complications, an increased likelihood of developing cancer and cardiovascular diseases, and greater difficulty in glycemic control. Despite substantial evidence highlighting the detrimental effects of smoking on individuals with diabetes, national surveys from the 1990s indicated similar smoking prevalence rates between individuals with and without diabetes (27.3% and 25.9%, respectively). Although various smoking cessation methods are available, the success rate of quitting remains low, necessitating novel intervention strategies.
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are widely used in the treatment of type 2 diabetes. They exert hypoglycemic effects by stimulating insulin secretion in a glucose-dependent manner, inhibiting glucagon secretion, enhancing glucose uptake in muscle and adipose tissue, suppressing hepatic glucose production, delaying gastric emptying, and reducing appetite. Existing studies suggest that GLP-1 influences the brain's reward system, and GLP-1RAs have been shown to reduce nicotine dependence in animal models. Recent clinical research has demonstrated that GLP-1RAs can be used in combination with nicotine patches to facilitate smoking cessation. However, whether GLP-1RAs alone can directly promote smoking cessation in individuals with diabetes remains unclear. Therefore, this study aims to investigate the potential direct effects of GLP-1RAs on smoking cessation in patients with type 2 diabetes.
Recent studies have shown that smoking increases the risk of developing prediabetes and diabetes. Moreover, individuals with diabetes who smoke have a higher risk of all-cause mortality, worsened chronic diabetic complications, an increased likelihood of developing cancer and cardiovascular diseases, and greater difficulty in glycemic control. Despite substantial evidence highlighting the detrimental effects of smoking on individuals with diabetes, national surveys from the 1990s indicated similar smoking prevalence rates between individuals with and without diabetes (27.3% and 25.9%, respectively). Although various smoking cessation methods are available, the success rate of quitting remains low, necessitating novel intervention strategies.
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are widely used in the treatment of type 2 diabetes. They exert hypoglycemic effects by stimulating insulin secretion in a glucose-dependent manner, inhibiting glucagon secretion, enhancing glucose uptake in muscle and adipose tissue, suppressing hepatic glucose production, delaying gastric emptying, and reducing appetite. Existing studies suggest that GLP-1 influences the brain's reward system, and GLP-1RAs have been shown to reduce nicotine dependence in animal models. Recent clinical research has demonstrated that GLP-1RAs can be used in combination with nicotine patches to facilitate smoking cessation. However, whether GLP-1RAs alone can directly promote smoking cessation in individuals with diabetes remains unclear. Therefore, this study aims to investigate the potential direct effects of GLP-1RAs on smoking cessation in patients with type 2 diabetes.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Smoking Cessation Facilitated by Glucagon-like Peptide-1 (GLP-1) Analogues
NCT03204396
Glucagon-like Peptide-1
Smoking Cessation
Weight Change, Body
+1 more
COMPLETED
PHASE2
A Study of Oral GLP1RA RGT001-075 in Adults With Type 2 Diabetes
NCT05297045
Type 2 Diabetes Mellitus
TERMINATED
PHASE2
Real-world Evaluation of GLP-1 Receptor Agonists (GLP-1RA) on Efficacy and Persistence, Adherence and Therapeutic Inertia Among Type 2 Diabetes Adults With Obesity
NCT05535322
Type 2 Diabetes
Obesity
COMPLETED
Semaglutide GLP1 Agonists With Degludec Basal-bolus Insulin in Early Type 1 Diabetes to Basal-bolus
NCT06057077
Type 1 Diabetes
UNKNOWN
PHASE1/PHASE2
Endothelial and Metabolic Effects of Glucagon-like Peptide-1 (GLP-1) in Coronary Circulation in Patients With Type 2 Diabetes Mellitus
NCT00923962
Type 2 Diabetes Mellitus
COMPLETED
NA
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Diabetes has become an increasingly severe global health concern. In 2021, an estimated 537 million adults worldwide were living with diabetes, and this number is projected to rise to 783 million by 2045, reflecting a 46% increase. Against the backdrop of the rising global prevalence of diabetes, smoking has been identified as a major risk factor for its onset, as well as a contributor to poor glycemic control and the progression of chronic diabetes complications. Moreover, smoking is an independent risk factor for elevated HbA1c levels. It has been reported that for every additional 20 pack-years of smoking, HbA1c increases by 0.12%. A meta-analysis of 46 prospective studies revealed that smoking increases the risk of all-cause mortality in patients with diabetes by 48%, the risk of coronary heart disease by 54%, myocardial infarction by 52%, and stroke by 44%. Additionally, smoking has been linked to an increased incidence of proteinuria and diabetic nephropathy.
Despite over 50 years of global tobacco control efforts, smoking remains one of the greatest public health threats in history. Tobacco use is responsible for approximately 8 million deaths annually, with over 7 million attributed to direct smoking and around 1.3 million to second hand smoke exposure. Although numerous smoking cessation interventions are available, the success rate remains suboptimal, highlighting the need for novel strategies. Currently, a combination of pharmacotherapy and counseling is considered the most effective approach for smoking cessation. However, findings from two meta-analyses conducted in 2013 and 2016 suggest that outcomes remain unsatisfactory. The withdrawal symptoms and post-cessation weight gain associated with conventional smoking cessation methods are among the leading causes of relapse.
Patients with T2DM often experience increased hunger. Following smoking cessation, the appetite-suppressing effects of nicotine are diminished, leading to increased food intake. Additionally, smoking cessation may alter gut microbiota, further contributing to weight gain. However, weight gain does not negate the long-term benefits of smoking cessation, which significantly reduces the risk of cardiovascular diseases and all-cause mortality. When exploring novel smoking cessation therapies, it is essential to address both nicotine withdrawal syndrome and the adverse metabolic effects of smoking cessation, such as weight gain, to maximize cessation success rates.
Glucagon-like peptide-1 (GLP-1), a gut hormone, has garnered significant research interest. It is an incretin hormone secreted by intestinal L-cells in response to nutrient intake. GLP-1 acts on the hypothalamus to enhance satiety and reduce food intake while also delaying gastric emptying. GLP-1 receptor agonists (GLP-1RA) are widely used for the treatment of T2DM. They exert glucose-lowering effects by stimulating insulin secretion in a glucose-dependent manner, inhibiting glucagon secretion , increasing glucose uptake in muscle and adipose tissues, suppressing hepatic glucose production, delaying gastric emptying, and reducing appetite.
Furthermore, GLP-1 is implicated in the shared neurobiological mechanisms of addiction via the mesolimbic reward system. Endogenous GLP-1 is produced in the nucleus tractus solitarius (NTS) of the brainstem and acts as a neurotransmitter released in multiple brain regions involved in reward processing. This suggests that GLP-1 may modulate addiction-related behaviours by attenuating neural responses in reward-related brain regions. However, no studies have yet investigated the effects of GLP-1RA on smoking cessation in patients with T2DM. In particular, it remains unclear whether GLP-1RA, at standard therapeutic doses for T2DM, can simultaneously reduce nicotine dependence.
Neuroimaging studies have shown that chronic nicotine use induces cognitive, structural, and functional alterations in the brain. Functional imaging research has identified the insula as a critical region involved in smoking behaviour. A negative correlation has been observed between cortical thickness in insular subregions and nicotine dependence. Additionally, functional imaging studies have demonstrated a positive correlation between nicotine dependence and activation of the anterior and posterior insula in response to smoking-related cues. Recent research has further revealed a negative correlation between nicotine dependence and connectivity between the left and right dorsal and left ventral anterior insula and the superior parietal lobule (SPL), including the left precuneus. The insula has thus been identified as a potential target for nicotine dependence treatment. Moreover, the left praecuneus has been proposed as a neuroimaging biomarker for nicotine addiction, with regional homogeneity (ReHo) values in the right superior frontal gyrus and left praecuneus distinguishing nicotine-dependent individuals.
To date, no studies have investigated nicotine dependence in patients with T2DM. Based on these findings, we hypothesize that GLP-1RA may modulate neural responses in reward-processing regions of the brain, thereby reducing nicotine dependence and cigarette consumption in patients with T2DM.
Despite over 50 years of global tobacco control efforts, smoking remains one of the greatest public health threats in history. Tobacco use is responsible for approximately 8 million deaths annually, with over 7 million attributed to direct smoking and around 1.3 million to second hand smoke exposure. Although numerous smoking cessation interventions are available, the success rate remains suboptimal, highlighting the need for novel strategies. Currently, a combination of pharmacotherapy and counseling is considered the most effective approach for smoking cessation. However, findings from two meta-analyses conducted in 2013 and 2016 suggest that outcomes remain unsatisfactory. The withdrawal symptoms and post-cessation weight gain associated with conventional smoking cessation methods are among the leading causes of relapse.
Patients with T2DM often experience increased hunger. Following smoking cessation, the appetite-suppressing effects of nicotine are diminished, leading to increased food intake. Additionally, smoking cessation may alter gut microbiota, further contributing to weight gain. However, weight gain does not negate the long-term benefits of smoking cessation, which significantly reduces the risk of cardiovascular diseases and all-cause mortality. When exploring novel smoking cessation therapies, it is essential to address both nicotine withdrawal syndrome and the adverse metabolic effects of smoking cessation, such as weight gain, to maximize cessation success rates.
Glucagon-like peptide-1 (GLP-1), a gut hormone, has garnered significant research interest. It is an incretin hormone secreted by intestinal L-cells in response to nutrient intake. GLP-1 acts on the hypothalamus to enhance satiety and reduce food intake while also delaying gastric emptying. GLP-1 receptor agonists (GLP-1RA) are widely used for the treatment of T2DM. They exert glucose-lowering effects by stimulating insulin secretion in a glucose-dependent manner, inhibiting glucagon secretion , increasing glucose uptake in muscle and adipose tissues, suppressing hepatic glucose production, delaying gastric emptying, and reducing appetite.
Furthermore, GLP-1 is implicated in the shared neurobiological mechanisms of addiction via the mesolimbic reward system. Endogenous GLP-1 is produced in the nucleus tractus solitarius (NTS) of the brainstem and acts as a neurotransmitter released in multiple brain regions involved in reward processing. This suggests that GLP-1 may modulate addiction-related behaviours by attenuating neural responses in reward-related brain regions. However, no studies have yet investigated the effects of GLP-1RA on smoking cessation in patients with T2DM. In particular, it remains unclear whether GLP-1RA, at standard therapeutic doses for T2DM, can simultaneously reduce nicotine dependence.
Neuroimaging studies have shown that chronic nicotine use induces cognitive, structural, and functional alterations in the brain. Functional imaging research has identified the insula as a critical region involved in smoking behaviour. A negative correlation has been observed between cortical thickness in insular subregions and nicotine dependence. Additionally, functional imaging studies have demonstrated a positive correlation between nicotine dependence and activation of the anterior and posterior insula in response to smoking-related cues. Recent research has further revealed a negative correlation between nicotine dependence and connectivity between the left and right dorsal and left ventral anterior insula and the superior parietal lobule (SPL), including the left precuneus. The insula has thus been identified as a potential target for nicotine dependence treatment. Moreover, the left praecuneus has been proposed as a neuroimaging biomarker for nicotine addiction, with regional homogeneity (ReHo) values in the right superior frontal gyrus and left praecuneus distinguishing nicotine-dependent individuals.
To date, no studies have investigated nicotine dependence in patients with T2DM. Based on these findings, we hypothesize that GLP-1RA may modulate neural responses in reward-processing regions of the brain, thereby reducing nicotine dependence and cigarette consumption in patients with T2DM.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Diabetes Mellitus, Type 2
Nicotine Dependence, Cigarettes
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
TREATMENT
Blinding Strategy
SINGLE
Participants
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
GLP-1 group
Group Type
EXPERIMENTAL
Application of GLP-1RAs drugs
Intervention Type
DRUG
The pharmacological intervention will be given as an add-on to the standardised psychosocial T2DM treatment paradigm. Patients self-inject Semaglutide once a week or use other GLP-1RAs
DPP-4i group
Group Type
ACTIVE_COMPARATOR
DPP-4i group
Intervention Type
DRUG
The pharmacological intervention will be given as an add-on to the standardised psychosocial T2DM treatment paradigm. Patients took the DPP-4i according to their actual needs.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Application of GLP-1RAs drugs
The pharmacological intervention will be given as an add-on to the standardised psychosocial T2DM treatment paradigm. Patients self-inject Semaglutide once a week or use other GLP-1RAs
Intervention Type
DRUG
DPP-4i group
The pharmacological intervention will be given as an add-on to the standardised psychosocial T2DM treatment paradigm. Patients took the DPP-4i according to their actual needs.
Intervention Type
DRUG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Male patients aged 18-75 years.
2. Diagnosis of type 2 diabetes mellitus (T2DM) based on the World Health Organization (WHO) criteria.
3. A history of smoking for at least one year.
4. Fagerström Test for Nicotine Dependence (FTND) score ≥4.
5. Eligible for treatment with glucagon-like peptide-1 receptor agonists (GLP1-RAs) or dipeptidyl peptidase-IV (DPP-IV) inhibitors but have not previously used these medications.
6. Patients who fully understand the study, voluntarily participate, and sign the informed consent form.
2. Diagnosis of type 2 diabetes mellitus (T2DM) based on the World Health Organization (WHO) criteria.
3. A history of smoking for at least one year.
4. Fagerström Test for Nicotine Dependence (FTND) score ≥4.
5. Eligible for treatment with glucagon-like peptide-1 receptor agonists (GLP1-RAs) or dipeptidyl peptidase-IV (DPP-IV) inhibitors but have not previously used these medications.
6. Patients who fully understand the study, voluntarily participate, and sign the informed consent form.
Exclusion Criteria
1. Diagnosis of type 1 diabetes or other specific types of diabetes.
2. Presence of diabetic ketoacidosis or severe diabetic complications.
3. Patients with severe cardiovascular, hepatic, renal, neurological, immune, or hematological diseases.
4. Presence of severe infections, malignancies, recent surgeries, or major trauma.
5. A history of severe recurrent hypoglycemia.
6. Severe gastrointestinal disorders, such as gastroparesis.
7. Poor adherence or inability to attend scheduled follow-up visits.
8. A history of pancreatitis or a high risk of developing pancreatitis.
9. Presence of severe psychiatric disorders, including schizophrenia, paranoid psychosis, bipolar disorder, or intellectual disability.
10. Contraindications to magnetic resonance imaging (MRI), such as metallic implants, pacemakers, or claustrophobia.
\-
2. Presence of diabetic ketoacidosis or severe diabetic complications.
3. Patients with severe cardiovascular, hepatic, renal, neurological, immune, or hematological diseases.
4. Presence of severe infections, malignancies, recent surgeries, or major trauma.
5. A history of severe recurrent hypoglycemia.
6. Severe gastrointestinal disorders, such as gastroparesis.
7. Poor adherence or inability to attend scheduled follow-up visits.
8. A history of pancreatitis or a high risk of developing pancreatitis.
9. Presence of severe psychiatric disorders, including schizophrenia, paranoid psychosis, bipolar disorder, or intellectual disability.
10. Contraindications to magnetic resonance imaging (MRI), such as metallic implants, pacemakers, or claustrophobia.
\-
Minimum Eligible Age
18 Years
Maximum Eligible Age
75 Years
Eligible Sex
MALE
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shanghai East Hospital
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
jun Song, doctoral degree
Role: STUDY_DIRECTOR
East Hospital, Tongji University School of Medicine, Shanghai
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Endocrinology, East Hospital, Tongji University School of Medicine, 150 Jimo Road, Shanghai
Shanghai, Shanghai Municipality, China
Site Status
Countries
Review the countries where the study has at least one active or historical site.
China
References
Explore related publications, articles, or registry entries linked to this study.
Willenborg J, Menzel W, Vetten HJ, Maiss E. Molecular characterization of two alphacryptovirus dsRNAs isolated from Daucus carota. Arch Virol. 2009;154(3):541-3. doi: 10.1007/s00705-009-0314-z. Epub 2009 Jan 23. No abstract available.
Reference Type
BACKGROUND
Kondoh H, Takagi S, Nomura K, Okada TS. Transdifferentiation of putative neuronal cells of neural retina into lens: A demonstration by chick-quail chimeric cultures. Wilehm Roux Arch Dev Biol. 1983 Sep;192(5):256-261. doi: 10.1007/BF00848657.
Reference Type
BACKGROUND
Gomez LA, Patino PJ, Novaira HJ, Morales MM, Condino-Neto A. A single nucleotide polymorphism in the promoter region of theNCF-2 gene. Am J Hematol. 2007 Dec;82(12):1124-5. doi: 10.1002/ajh.21015. No abstract available.
Reference Type
BACKGROUND
Scanlon TC, Dostal SM, Griswold KE. A high-throughput screen for antibiotic drug discovery. Biotechnol Bioeng. 2014 Feb;111(2):232-43. doi: 10.1002/bit.25019. Epub 2013 Aug 29.
Reference Type
BACKGROUND
Zhang HB, Scheuring CF, Zhang M, Zhang Y, Wu CC, Dong JJ, Li Y. Construction of BIBAC and BAC libraries from a variety of organisms for advanced genomics research. Nat Protoc. 2012 Feb 16;7(3):479-99. doi: 10.1038/nprot.2011.456.
Reference Type
BACKGROUND
Gallmeier K, Becker E, Kirsten A, Wolke G, Manuwald O, Meyer H, Magnussen H, Nowak D, Heinrich J. Prediction of new-onset asthma and nasal allergy by skin prick test and RAST in a cohort of adults. Eur Respir J. 2014 Jan;43(1):92-102. doi: 10.1183/09031936.00012813. Epub 2013 Sep 13.
Reference Type
BACKGROUND
Fernandez Rodriguez R. Language, Science and Globalization in the Eighteenth Century. Ber Wiss. 2023 Mar;46(1):38-53. doi: 10.1002/bewi.202200040. Epub 2023 Mar 6.
Reference Type
BACKGROUND
Ismail E, Orlando G, Corradini ML, Amerio P, Romani GL, Merla A. Differential diagnosis of Raynaud's phenomenon based on modeling of finger thermoregulation. Physiol Meas. 2014 Apr;35(4):703-16. doi: 10.1088/0967-3334/35/4/703. Epub 2014 Mar 12.
Reference Type
BACKGROUND
Patinadan PV, Tan-Ho G, Choo PY, Low CX, Ho AHY. 'Food for Life and Palliation (FLiP)': a qualitative study for understanding and empowering dignity and identity for terminally ill patients in Asia. BMJ Open. 2021 Apr 13;11(4):e038914. doi: 10.1136/bmjopen-2020-038914.
Reference Type
BACKGROUND
Perez H, Tah JHM, Mosavi A. Deep Learning for Detecting Building Defects Using Convolutional Neural Networks. Sensors (Basel). 2019 Aug 15;19(16):3556. doi: 10.3390/s19163556.
Reference Type
BACKGROUND
Nielsen PA. Mutagenicity studies on complex environmental mixtures: selection of solvent system for extraction. Mutat Res. 1992 Jan-Mar;276(1-2):117-23. doi: 10.1016/0165-1110(92)90060-m.
Reference Type
BACKGROUND
Tao L, Pereira MA. Quantification of carvone, cineole, perillaldehyde, perillyl alcohol and sobrerol by isocratic high-performance liquid chromatography. J Chromatogr A. 1998 Jan 9;793(1):71-6. doi: 10.1016/s0021-9673(97)00867-4.
Reference Type
BACKGROUND
Lue NF, Kornberg RD. A possible role for the yeast TATA-element-binding protein in DNA replication. Proc Natl Acad Sci U S A. 1993 Sep 1;90(17):8018-22. doi: 10.1073/pnas.90.17.8018.
Reference Type
BACKGROUND
Kragh-Hansen U, Donaldson D, Jensen PH. The glycan structure of albumin Redhill, a glycosylated variant of human serum albumin. Biochim Biophys Acta. 2001 Nov 26;1550(1):20-6. doi: 10.1016/s0167-4838(01)00264-3.
Reference Type
BACKGROUND
Stewart DL, Cook LN, Rabalais GP. Successful use of extracorporeal membrane oxygenation in a newborn with herpes simplex virus pneumonia. Pediatr Infect Dis J. 1993 Feb;12(2):161-2. doi: 10.1097/00006454-199302000-00014. No abstract available.
Reference Type
BACKGROUND
Calman KC, Mouatt BR. Fluoridation of drinking water. It's safe and it reduces dental decay. BMJ. 1993 Aug 7;307(6900):386. doi: 10.1136/bmj.307.6900.386-c. No abstract available.
Reference Type
BACKGROUND
Green G, Pool R, Harrison S, Hart GJ, Wilkinson J, Nyanzi S, Whitworth JA. Female control of sexuality: illusion or reality? Use of vaginal products in south west Uganda. Soc Sci Med. 2001 Feb;52(4):585-98. doi: 10.1016/s0277-9536(00)00162-3.
Reference Type
BACKGROUND
Pan A, Wang Y, Talaei M, Hu FB, Wu T. Relation of active, passive, and quitting smoking with incident type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2015 Dec;3(12):958-67. doi: 10.1016/S2213-8587(15)00316-2. Epub 2015 Sep 18.
Reference Type
BACKGROUND
Ehdaie B, Mason MD, Peters CA, Corbett ST. Transurethral placement of vaginal contraceptive device in a patient with neurogenic bladder: a case report and review of the literature. J Pediatr Urol. 2013 Apr;9(2):e107-10. doi: 10.1016/j.jpurol.2012.11.008. Epub 2012 Dec 6.
Reference Type
BACKGROUND
Karagiannis DA, Soublis V, Kandarakis A. A case of polypoidal choroidal vasculopathy. Periphery is equally important for such patients. Clin Interv Aging. 2009;4:315-7. doi: 10.2147/cia.s6193. Epub 2009 Jun 29.
Reference Type
BACKGROUND
Kang YA, Paik H, Zhang SY, Chen JJ, Olson OC, Mitchell CA, Collins A, Swann JW, Warr MR, Fan R, Passegue E. Secretory MPP3 reinforce myeloid differentiation trajectory and amplify myeloid cell production. J Exp Med. 2023 Aug 7;220(8):e20230088. doi: 10.1084/jem.20230088. Epub 2023 Apr 26.
Reference Type
BACKGROUND
Poku R, Amissah F, Alan JK. PI3K Functions Downstream of Cdc42 to Drive Cancer phenotypes in a Melanoma Cell Line. Small GTPases. 2023 Dec;14(1):1-13. doi: 10.1080/21541248.2023.2202612.
Reference Type
BACKGROUND
Hanson JA, Hsu FP, Jacob AT, Bota DA, Alexandru D. Antivascular endothelial growth factor antibody for treatment of glioblastoma multiforme. Perm J. 2013 Fall;17(4):68-74. doi: 10.7812/TPP/13-081.
Reference Type
BACKGROUND
Ogun SA, Tewari R, Otto TD, Howell SA, Knuepfer E, Cunningham DA, Xu Z, Pain A, Holder AA. Targeted disruption of py235ebp-1: invasion of erythrocytes by Plasmodium yoelii using an alternative Py235 erythrocyte binding protein. PLoS Pathog. 2011 Feb;7(2):e1001288. doi: 10.1371/journal.ppat.1001288. Epub 2011 Feb 17.
Reference Type
BACKGROUND
Hu Y, Zong G, Liu G, Wang M, Rosner B, Pan A, Willett WC, Manson JE, Hu FB, Sun Q. Smoking Cessation, Weight Change, Type 2 Diabetes, and Mortality. N Engl J Med. 2018 Aug 16;379(7):623-632. doi: 10.1056/NEJMoa1803626.
Reference Type
BACKGROUND
Galcheva SV, Martorana D, Iotova VM, Yotov Y, Neri TM, Street ME. Associations between two single nucleotide polymorphisms of the adiponectin gene, its circulating concentrations and cardiometabolic risk factors in prepubertal children with and without abdominal obesity. J Endocrinol Invest. 2013 Nov;36(10):869-75. doi: 10.3275/8972. Epub 2013 May 22.
Reference Type
BACKGROUND
Palamar M, Degirmenci C, Ertam I, Yagci A. Ocular response analyser measurements and central corneal thickness in ocular rosacea patients. Int Ophthalmol. 2017 Feb;37(1):7-11. doi: 10.1007/s10792-016-0218-3. Epub 2016 Mar 12.
Reference Type
BACKGROUND
Clasen FJ, Pierneef RE, Slippers B, Reva O. EuGI: a novel resource for studying genomic islands to facilitate horizontal gene transfer detection in eukaryotes. BMC Genomics. 2018 May 3;19(1):323. doi: 10.1186/s12864-018-4724-8.
Reference Type
BACKGROUND
Dorum G, Kaur N, Gysi M. Pedigree-based relationship inference from complex DNA mixtures. Int J Legal Med. 2017 May;131(3):629-641. doi: 10.1007/s00414-016-1526-x. Epub 2017 Jan 19.
Reference Type
BACKGROUND
Wittmann C, Heinzle E. Application of MALDI-TOF MS to lysine-producing Corynebacterium glutamicum: a novel approach for metabolic flux analysis. Eur J Biochem. 2001 Apr;268(8):2441-55. doi: 10.1046/j.1432-1327.2001.02129.x.
Reference Type
BACKGROUND
Correction to Lancet Diabetes Endocrinol 2022; 10: 741-60. Lancet Diabetes Endocrinol. 2022 Nov;10(11):e11. doi: 10.1016/S2213-8587(22)00280-7. Epub 2022 Oct 7. No abstract available.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EC.D(BG).025.04.0
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Glucagon-like Peptide 1 (GLP-1) and Endothelial Dysfunction in Metabolic Syndrome
NCT00856700
COMPLETED
NA
Relationship Between Improvement in Insulin Secretion and Decrease in HbA1c in GLP-1 RA Therapy in T2DM Patients
NCT04135287
UNKNOWN
PHASE4
GLP-1/Basal Insulin Combination Therapy
NCT02895672
COMPLETED
Study TO Prevent Diabetes With Short-term Insulin Glargine Only
NCT01276912
UNKNOWN
NA
Effect of Weekly GLP1 Agonist Treatment in "Double Diabetes"
NCT05305794
RECRUITING
PHASE3
The Progress of Diabetes After Supaglutide Treatment in Type 2 Diabetes Patients
NCT06605287
RECRUITING
Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of JY09
NCT04354090
COMPLETED
PHASE1
GLP-1 Analogue Treatment in Uncontrolled Type 1 Diabetic Patients
NCT01592279
UNKNOWN
PHASE4
GLP1-RAs Effects on Inflammatory and Endothelial Biomarkers in T2DM
NCT07314684
RECRUITING
PHASE4
Effect of a Glucagon Like Peptide 1 (GLP1) Booster in Healthy Humans
NCT06333496
COMPLETED
NA
Glucagon Like Peptide 1 (GLP-1) Booster™ RCT Study
NCT07141472
COMPLETED
NA
Effects of Glucagon Like Peptide-1 on Haemodynamic Parameters
NCT02490176
UNKNOWN
NA
Combined Liraglutide and Metformin Therapy in Women With Previous Gestational Diabetes Mellitus (GDM)
NCT01234649
COMPLETED
PHASE3
GLP-1 Infusion and Long-Time Fasting
NCT00285896
COMPLETED
NA
Dietary Insights and Nutrition Experiences in Adults on GLP-1 Therapy - A Study on Diet Quality Changes in Adults on GLP-1 Therapy
NCT07313384
RECRUITING
Effects of Glucagon Like Peptide-1(GLP-1) and Liraglutide on Brain Satiety and Reward Circuits and Feeding Behavior in Diabetes
NCT01363609
COMPLETED
NA
Comprehensive Clinical Evaluation Study of GLP-1RA
NCT06686134
RECRUITING
The Effect of Glycemic Control and of GLP-1 Receptor Agonism on Islet GLP-1 in People With Type 1 and Type 2 Diabetes
NCT06976619
RECRUITING
PHASE2
a Study of JY09 in Chinese Healthy Subjects
NCT02971722
UNKNOWN
PHASE1
The Role of Endogenous Glucagon-like Peptide 1 (GLP-1) in Type 2 Diabetes Mellitus (T2DM)
NCT01449019
COMPLETED
PHASE1
Liraglutide in Type 1 Diabetes
NCT01722240
COMPLETED
PHASE3
Effect of GLP-1 Receptor (GLP-1R) Agonists on Cardiac Function and on Epicardial Adipose Tissue (EAT) Volume and on Myocardial TG Content in Obese Diabetics
NCT02042664
COMPLETED
PHASE3
Glucose-induced Glucagon-like Peptide 1 (GLP-1) Secretion in NAFLD Patients Compared to Healthy Controls
NCT01674972
COMPLETED
GLP-1 REceptor Agonists and Real World EvIdeNce
NCT03959865
UNKNOWN
GLP-1 and Hypoglycemia
NCT01858896
ACTIVE_NOT_RECRUITING
EARLY_PHASE1